AMPX - Amprius Technologies Inc
Executive Summary
Amprius Technologies Inc (AMPX) is a Fremont, California-based manufacturer of high-energy and high-power lithium-ion battery cells built around a silicon-anode chemistry that the company states delivers the industry's highest energy density. Its products are positioned for applications where energy density and weight are critical, including unmanned aerial systems, defence platforms, and premium electric mobility programmes, giving it a niche but defensible position at the high-performance end of the lithium-ion market.
The investment case rests on the execution of US-based production scale-up, anchored by a recently announced Nanotech manufacturing partnership and a $75 million Department of War grant to expand NDAA-compliant battery capacity for military drone programmes, alongside raised forward guidance that supports the published $23 consensus target. The primary risk is that the company is loss-making, with negative EPS of around minus 0.29, and may need to raise additional dilutive capital to fund the build-out; silicon-anode cell durability at scale remains a technical question that further funding rounds will not resolve.
OPPORTUNISTIC BUY. Conviction Score: 63/100. The view would move to a higher-conviction tier on evidence of durable, low-defect-rate cell production and a non-dilutive or only modestly dilutive financing path, and would be downgraded if the company signals that further capital is required on punitive terms or if silicon-anode degradation materially shortens real-world cycle life.
Thesis break: A clearly announced dilutive equity raise at a material discount to the prevailing share price to fund continued losses, evidence of silicon-anode cycle-life failures in customer programmes, or loss of the Department of War grant as a contracted award.
Business Model
Amprius generates revenue primarily through the sale of its high-energy-density silicon-anode lithium-ion battery cells, with demand concentrated in unmanned aerial systems, defence and premium electric mobility programmes where customers are willing to pay a premium for cells that the company claims offer the highest energy density in the industry. Customer relationships are weighted towards US defence and government-aligned programmes, which the recent $75 million Department of War grant and the Nanotech manufacturing partnership reinforce, and the company is positioning itself to benefit from onshoring of critical battery supply chains under the National Defence Authorisation Act framework.
The competitive moat, to the extent one exists, rests on proprietary silicon-anode chemistry, the associated manufacturing know-how, and the ability to qualify cells into defence programmes where the certification pathway itself is a barrier to entry. The economic reality, however, is that Amprius remains a pre-scale manufacturer: the company is loss-making on an earnings basis, and revenue is not yet at a level where fixed costs are absorbed, which leaves gross margin profile vulnerable to production mix and capacity utilisation in the near term. Scaling the Fremont footprint and any new US production lines to a point where operating leverage becomes visible is therefore the central operating question for the next twelve months.
Financial Snapshot
Recent Catalysts
[28 September 2026] - Amprius announced that it had secured a $75 million grant from the Department of War to scale NDAA-compliant, American-made high-energy-density battery production targeted at military drone applications. Source: Amprius Technologies press release (ir.amprius.com).
[5 August 2026] - Amprius published its Q2 2026 results via an 8-K filed with the SEC on 4 August 2026, reporting financial results and an accompanying earnings release. Source: SEC 8-K filing (Form 8-K dated 4 August 2026) and Amprius press release (Business Wire).
[Q1 2026, period ended 31 March 2026] - Amprius released Q1 2026 financial results, including the earnings release, presentation materials and 10-Q filing. Source: Amprius investor relations financial results page (ir.amprius.com).
[2026, undated within provided research] - Amprius entered a manufacturing partnership with Nanotech, cited as a concrete catalyst supporting the investment thesis. Source: Company press release referenced in Amprius investor relations materials.
[Next earnings, date not confirmed in research] - Amprius's next scheduled earnings announcement is referenced on Marketbeat and Nasdaq earnings calendars; the specific date is not confirmed in the data provided. Source: Marketbeat and Nasdaq earnings pages.
Thesis Evaluation
Bull Case (29% weight)
Amprius converts the $75 million Department of War grant and the Nanotech partnership into ramped, on-schedule US production, defence and aerospace customers absorb the additional capacity at acceptable gross margins, and the company secures a non-dilutive or only modestly dilutive path to fund the remaining build-out. EPS improves materially and the share price rerates towards the published $23 consensus area. Price target $23.00, 12-month horizon.
Base Case (51% weight)
Production scales on plan but margins remain under pressure while volumes ramp, and one further capital raise, moderately dilutive, is required to complete the build-out. The share price moves towards, but does not reach, the consensus target as execution progresses. Price target $14.00, 12-month horizon.
Bear Case (20% weight)
The silicon-anode durability question that the 10-K flags translates into field-level warranty or qualification issues, and the company is forced to raise capital on punitive terms to keep the build-out funded. Revenue growth disappoints and the share price retraces towards the 52-week low set earlier in the year. Price target $6.00, 12-month horizon.
Key Risks
- Continuing losses and uncertain path to profitability: Amprius has a multi-year history of operating losses, posted negative EPS of approximately minus 0.29 in the most recent reported period, and the 10-K states that significant expenses and continuing losses are expected for the foreseeable future. Estimated probability: high. Impact: severe.
- Need for additional dilutive capital: The 10-K disclosure warns that Amprius may require additional capital and that future financing may not be available on commercially reasonable terms, with the bear scenario centring on a punitive equity raise that materially dilutes existing shareholders. Estimated probability: moderate. Impact: severe.
- Silicon-anode durability and cell quality at scale: The filing highlights that silicon particles can expand by as much as 300% during charging, raising the question of whether the company can maintain cycle life and defect rates acceptable to defence and aerospace customers as production volumes rise. Estimated probability: moderate. Impact: severe.
- Customer concentration in defence and government programmes: Revenue and grant support are concentrated in US defence and NDAA-compliant drone programmes, so any shift in Department of War priorities, budget timing or procurement schedules could disproportionately affect Amprius. Estimated probability: low. Impact: moderate.
- Limited public float and elevated share-price volatility: AMPX trades well below its 52-week high of USD24.23 and near its 52-week low of USD7.71, indicating a wide trading range that can amplify mark-to-market losses around catalysts and earnings. Estimated probability: high. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: growth-oriented investors with a high risk tolerance and a minimum holding period of 12 to 24 months who are comfortable with loss-making, capital-raising risk and want exposure to US defence onshoring, next-generation battery chemistry and government-funded industrial scale-up theses. The position should be sized as a small, speculative allocation within a diversified portfolio rather than a core holding, given the balance-sheet and execution risks.
Avoid if: investors require current profitability, dividend income, or a low-volatility profile, and those who cannot tolerate the possibility of further dilutive equity issuance at a lower share price, or who are unwilling to accept that defence procurement timing alone can move the share price materially. Short-term traders and investors with a sub-twelve-month horizon should also avoid, as the investment case is built on multi-quarter execution of production scale-up.
Recommendation
OPPORTUNISTIC BUY - 63/100. The tier reflects a constructive view on hard, dated catalysts, namely the $75 million Department of War grant, the Nanotech manufacturing partnership and the raised forward guidance, offset by the company-specific risks of ongoing losses, capital-raising need and silicon-anode durability that the 10-K disclosure makes explicit. The call would be upgraded to a higher tier on evidence of durable, low-defect-rate cell output, a non-dilutive or only modestly dilutive financing path, and a clear path to gross margin improvement as defence volumes ramp. It would be downgraded if the company signals that further capital is required on punitive terms, if silicon-anode degradation materially shortens cycle life in customer programmes, or if defence procurement timing slips in a way that pushes the cash break-out point further out. At the current price of $9.67 the shares trade above our buy ceiling of $8.67: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $15.01, 55% above the current price of $9.67 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $8.67 - below this level the upside to the base-case target ($14.00) is at least 2x the downside to the bear case ($6.00), the minimum risk/reward we require before committing new capital.
between $8.67 and $14.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $14.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 29%.
if A clearly announced dilutive equity raise at a material discount to the prevailing share price to fund continued losses, evidence of silicon-anode cycle-life failures in customer programmes, or loss of the Department of War grant as a contracted award, regardless of price - the bear target of $6.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 63/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 63 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: public news flow drawn from company press releases, regulatory filings referenced on EDGAR, Amprius investor relations materials, and financial news wires covering the grant announcement, Q2 2026 results and Q1 2026 results; sentiment is interpreted only from these public sources and from earnings call transcripts and presentations hosted on the company's investor relations site.
Primary source types: SEC filings including the 10-K, 10-Q and 8-K disclosures, Amprius Technologies press releases and earnings releases, Amprius investor relations presentations and webcasts, and financial news wires reporting on the Department of War grant and the Nanotech manufacturing partnership.
Key sources
- Amprius Technologies (AMPX) Earnings Date and Reports 2026 $AMPX
- Amprius Technologies, Inc. (AMPX)
- Amprius Technologies, Inc. (AMPX) Stock Price, News, Quote & History - Yahoo Finance
- Amprius Technologies (AMPX) Stock Price & Overview
- AMPX Stock Quote Price and Forecast | CNN
- Amprius Technologies (AMPX) Is Up 23.4% After Raising 2026 Guidance Amid Improving Manufacturing Economics - Simply Wall St News
- Amprius Technologies, Inc. (AMPX) Announces a Manufacturing Partnership with Nanotech Energy
- News & Events :: Amprius Technologies, Inc. (AMPX)
- Financial Results :: Amprius Technologies, Inc. (AMPX)
- Amprius Technologies Inc (AMPX) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com
Data correct as of 2026-10-04